Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861193 | 0.86 | TRPA1 (0.32) | TRPA1PDE4B | |
| SCHEMBL7661432 | 0.73 | TDP1 (0.40) | — | |
| SCHEMBL52343 | 0.73 | HTR2A (0.31) | — | |
| SCHEMBL8026331 | 0.70 | HIF1A (0.33) | TRPA1PDE4B | |
| SCHEMBL2965836 | 0.67 | TRPA1 (0.47) | TRPA1 | |
| SCHEMBL4783956 | 0.67 | BACE1 (0.32) | TRPA1PDE4B | |
| SCHEMBL18989196 | 0.66 | HTR2C (0.36) | PDE4B | |
| SCHEMBL1140723 | 0.65 | RXRA (0.44) | — | |
| SCHEMBL2224319 | 0.65 | KDM1A (0.35) | PDE4B | |
| SCHEMBL14861179 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874369-A | 1,3, 4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-12-31 | — | — | CN | disclosed |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-20 | — | — | US | disclosed |
| EP-2899183-B1 | Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-9725435-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160289209-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| US-9394276-B2 | Substituted 1,2,3,4-tetrahydro-2,6-naphthyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150315200-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-05 | — | — | US | disclosed |
| US-9108951-B2 | Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2899183-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20140275061-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| EP-2766345-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013055984-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-6358974-B1 | USED AS AS MODULATORS OF DOPAMINE D.SUB.3 RECEPTORS, IN THERAPY AS ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-19 | — | — | US | disclosed |
| EP-1137638-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000024717-A2 | ISOQUINOLINE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000466-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors | F12, TFPI, F11 | TRPA1 4399/4885PDE4B 1047/4885 |
| US-20170305880-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | TRPA1 4222/4885PDE4B 1784/4885 |
| US-20150315200-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | TRPA1 4222/4885PDE4B 1784/4885 |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | TFPI, F12, F11 | TRPA1 4108/4885PDE4B 1597/4885 |
| US-20140275061-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | TRPA1 4222/4885PDE4B 1784/4885 |
| US-20180265494-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | TRPA1 4222/4885PDE4B 1784/4885 |
| US-20160289209-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | TRPA1 4222/4885PDE4B 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.